ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinso
Molecular Weight:
512.04
Purity:
99.21
CAS Number:
[1251528-23-0]
Formula:
C27H34ClN5O3
Target:
CCR
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted